With H Pylori, High dose of PPIs tied to gastric intestinal metaplasia and cancer: Study
There are multiple factors for gastric intestinal metaplasia.
The researchers conducted a large retrospective study and evaluated whether cumulative proton pump inhibitor dose is associated with the diagnosis of gastric intestinal metaplasia while controlling for multiple variables.
They found that patients positive for Helicobacter pylori (H. pylori), high cumulative proton pump inhibitor (PPI) doses were found to be significantly associated with precancerous gastric intestinal metaplasia (GIM) in a dose-dependent manner.
Emerging evidence from several observational studies suggests that the long-term use of proton pump inhibitors (PPIs) is associated with a higher risk of gastric cancer development, especially in patients who have undergone Helicobacter pylori